Infobox company company name Genentech, Inc. company logo Image Genentech.svg 210px company type Wholly ... L. Moore br Denise Smith Hams, HR br Arthur D. Levinson, Ph.D., Chairman, Genentech Board of Directors ... , Zenapax num employees c. 11,000 March 1, 2011 homepage http www.gene.com www.gene.com Genentech ... The Birth of Biotechnology author Eugene Russo work Nature date 2003 01 23 ref ref name Genentech CorporateOverview Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start the first biotechnology company, Genentech. cite web url http www.gene.com gene about corporate index.jsp?hl en&q genentech title Corporate Overview author Genentech ref Trailing the founding of Cetus by five years, it was an important step in the evolution of the biotechnology industry. ref name Nature2003 01 23 ref name Genentech .... Investing 500 each, they capitalized a new business, Genentech, to seek practical uses for Boyer ... in 1978. As of February 2011, Genentech employed more than 11,000 people. ref cite news url http ... Hoffmann La Roche now completely owns Genentech after completing its purchase on March 26, 2009 for approximately ... 2008 09 26 title Roche Makes 43.7B Bid for Genentech work Genetic Engineering & Biotechnology News url http www.genengnews.com news bnitem.aspx?name 39080941 ref Research Genentech markets itself ... molecular biology to protein chemistry to bioinformatics and physiology. Genentech scientists in these various ... , Tissue Growth and Repair, Neuroscience and Infectious Disease. Genentech s recent hiring ... development group at Oceanside, Genentech s research facilities are located on the South San Francisco ... right Building 32, one of the Genentech headquarters newer buildings Genentech s corporate headquarters ..., California and in Oceanside, California . On March 17, 2006, Genentech announced its decision to construct ... Portland as of 2006 alt which is expected to be operational by 2010 . In December 2006, Genentech ... more details
No footnotes date February 2008 Infobox SCOTUS case Litigants MedImmune, Inc. v. Genentech, Inc. ArgueDate October 4 ArgueYear 2006 DecideDate January 9 DecideYear 2007 FullName MedImmune, Inc. v. Genentech, Inc. Docket 05 608 USVol 549 USPage 118 Citation Prior Subsequent Holding Contrary to respondents assertion that only a freestanding patent invalidity claim is at issue, the record establishes that petitioner has raised and preserved the contract claim that, because of patent invalidity, unenforceability, and noninfringement, no royalties are owing. 427 F. 3d 958, reversed and remanded. SCOTUS 2006 Majority Scalia JoinMajority Roberts, Stevens, Kennedy, Souter, Ginsburg, Breyer, Alito Dissent Thomas LawsApplied MedImmune, Inc. v. Genentech, Inc. , Case citation 549 U.S. 118 2007 was a decision ... from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech ... of the dispute was a lengthy interference proceeding between Genentech and Celltech which led ... Genentech a patent term of 29 years. MedImmune was a licensee of the later Cabilly patent, but argued ... States Patent and Trademark Office USPTO declared the patent invalid. Genentech appealed to the USPTO the ruling and the patent remained valid and enforceable until the appeal was concluded. Genentech ... Genentech and Celltech and their dispute over the original Cabilly patent 4,816,567 and the Celltech ... to Minimize Patent Royalty Payment Risks After Medimmune v. Genentech journal New York University ... biotech patents genentech claims rejected on patent which was subject of recent supreme court decision.html Genentech Claims Rejected on Patent Which Was Subject of Recent Supreme Court Decision . California ... on Genentech s 29 year old patent Patent Baristas Blog . February 22, 2006. http www.gazette.net ... 16, 2005. http www.californiabiotechlaw.com archives biotech patents genentech hit with adverse patent ruling.html Genentech Hit with Adverse Patent Ruling . California Biotech Law Blog . September ... more details
Alteon may refer to Alteon Corporation , part of Genentech , producers of Alagebrium Alteon Training an aircraft training school owned by The Boeing Company Alteon WebSystems a network products manufacturer disambig ... more details
Unreferenced date September 2007 The Cabilly patents are two US patents issued to Genentech which relate to the fundamental technology required for the artificial synthesis of antibody molecules . Citation needed date September 2007 The name refers to the lead inventor Shmuel Cabilly. There has been ongoing legal controversy surrounding these patents since the original filing in 1983. An interference between US patent 4,816,567 the original Cabilly patent issued to Genentech and US patent 4,816,397 the Boss patent issued to Celltech resulted in the issuance of a second Cabilly patent to Genentech in 2001. This new patent would therefore extend into 2018, an effective term of 29 years. A lawsuit filed by MedImmune , a licensee of the Cabilly patent, resulted in the United States Supreme Court case MedImmune, Inc. v. Genentech, Inc. which was decided in favor of MedImmune. Following the supreme court decision, the United States Patent and Trademark Office USPTO declared Genentech s patent invalid, but Genentech appealed that decision to the USPTO. The patent remained valid and enforceable until the process was completed. Genentech s Cabilly II patent 6,331,415 was then found, after USPTO reexamination, to be enforceable. MedImmune and Centocor have settled with Genentech 1 . Currently, two other challenges are in the courts. GlaxoSmithKline and Human Genome Sciences both are challenging the patent under antitrust law 1 . This is based on the settlement between Genentech and Celltech ... biotech patents genentech claims rejected on patent which was subject of recent supreme court decision.html Genentech Claims Rejected on Patent Which Was Subject of Recent Supreme Court Decision . California ... on Genentech s 29 year old patent Patent Baristas Blog . February 22, 2006. http www.gazette.net ... 16, 2005. http www.californiabiotechlaw.com archives biotech patents genentech hit with adverse patent ruling.html Genentech Hit with Adverse Patent Ruling . California Biotech Law Blog . September ... more details
Bob or Robert Swanson may refer to Robert A. Swanson , cofounder of Genentech, a biotech company Bob Swanson driver , Indianapolis 500 and midget car driver Robert Swanson inventor , whistle inventor hndis Swanson, Bob ... more details
This is a list of famous genetic engineers. For more information, see genetic engineering . Paul Berg created the first recombinant DNA molecules Herbert Boyer created the first genetically modified organism and co founded the first biotechnical company specialising in genetic engineering Genentech Stanley Cohen biochemist Stanley Cohen created the first genetically modified organism Rudolf Jaenisch created the first transgenic mouse Robert A. Swanson co founded the first biotechnical company specialising in genetic engineering Genentech Craig Venter leader of the group that made the first synthetic life synthetic genome Mycoplasma laboratorium Category Genetic engineering genetics stub ... more details
of Genentech 1999 to present and the chairman of Apple Inc. 2011 to present . He is the former chief executive officer of Genentech 1995 2009 and is also a member of Genentech s Scientific Research ... projects. In addition to serving as Chairman for Genentech and Apple Inc. Apple. Inc. ref name ... title Arthur Levinson Chairman of Genentech Inc. publisher Broad Institute ref Education He ... first Daniel S. last Levine title Executive of the Year Arthur Levinson drives Genentech work San Francisco Business Times date 2004 12 19 ref from where he was hired to Genentech by Herb Boyer . Career Levinson joined Genentech in 1980 as a research scientist and became vice president, Research ... vice president, Research and Development in 1993. In 1995, Levinson became Genentech s chief executive ... news press releases display.do?method print&id 4897 title Genentech Names Levinson as New Board Chair and Announces Appointment of Two New Directors publisher Genentech date 1999 09 22 ref In the same ... press release url http www.gene.com gene news press releases display.do?method print&id 4895 title Genentech ... Genentech date 1999 09 29 ref and was honored with the Corporate Leadership Award from the National ... awards.html title Past Awards and Recognition publisher Genentech ref Levinson was inducted into the Biotech ... google board first Doug last Aamoth title Genentech s And Apple Board Member Arthur Levinson Leaves ... http www.gene.com gene about corporate awards title Awards and Recognition publisher Genentech ref ... 2011 11 15 genentechs art levinson replaces steve jobs as chairman of apples board title Genentech ... DESCRIPTION is the chairman of Genentech 1999 to present , and former chief executive officer 1995 to 2009 . Levinson is also a member of Genentech s Scientific Research Board, which serves as an advisory ... more details
Arthur Riggs is the name of Arthur Riggs geneticist , geneticist who worked with Genentech to express the first artificial gene in bacteria Arthur Stanley Riggs 1879 1952 , American writer, editor and historian hndis Riggs, Arthur Short pages monitor This long comment was added to the page to prevent it from being listed on Special Shortpages. It and the accompanying monitoring template were generated via Template Long comment. Please do not remove the monitor template without removing the comment as well. ... more details
Primary Indication width 100 Company 2008 ref name Genentech 2008 10 K http www.sec.gov Archives edgar data 318771 000031877109000003 form10 k 2008.htm , Genentech 2008 10 K. ref ref name Pfizer 2008 ... d10k.htm , Ista Pharmaceuticals 2008 10 K. ref 2007 ref name Genentech 2007 10 K http www.sec.gov Archives edgar data 318771 000031877108000004 form10 k 2007.htm , Genentech 2007 10 K. ref ref name ... 930553 000119312508050141 d10k.htm , Ista Pharmaceuticals 2007 10 K. ref 2006 ref name Genentech 2006 10 K http www.sec.gov Archives edgar data 318771 000031877107000004 form10 k 2006.htm , Genentech ... 2005 ref name Genentech 2005 10 K http www.sec.gov Archives edgar data 318771 000031877106000005 form10 k.htm , Genentech 2005 10 K. ref ref name Pfizer 2005 10 K http www.sec.gov Archives edgar data ... data 64978 000095012306003031 y18212e10vk.htm , Merck 2005 10 K. ref 2004 ref name Genentech 2004 10 K http www.sec.gov Archives edgar data 318771 000031877105000003 dna 10k 2004.htm , Genentech 2004 ... 2004 10 K. ref 2003 ref name Genentech 2003 10 K http www.sec.gov Archives edgar data 318771 000031877104000002 dna 10k 2003.htm , Genentech 2003 10 K. ref ref name Pfizer 2003 10 K http www.sec.gov ... 000089256904000307 a96815e10vk.htm , Allergan 2003 10 K. ref 2002 ref name Genentech 2002 10 K http www.sec.gov Archives edgar data 318771 000031877103000002 dna 10k 2002.htm , Genentech 2002 10 ... y58494ex13.htm , Pfizer 2001 10 K. ref 2000 ref name Genentech 2000 10 K http www.sec.gov Archives edgar data 318771 000031877101500003 form10 k.txt , Genentech 2000 10 K. ref ref name Eli Lilly ... Pfizer 312 367 344 216 trastuzumab Herceptin HER2 positive metastatic breast cancer Genentech 1,382 ... small cell lung cancer NSCLC , renal cell carcinoma, HER2 negative breast cancer Genentech 2,686 2,296 1,746 1,132 554.6 erlotinib Tarceva Advanced metastatic non small cell lung cancer NSCLC Genentech ... 286.8 248.5 250.9 rituximab Rituxan Non Hodgkin s lymphoma and rheumatoid arthritis Genentech 2,587 ... more details
8 doi 10.1038 78412 pmid 10932141 issue 8 ref Clinical trials Genentech started clinical trial s on the drug in October 1996. ref cite web title Genentech Reports 1996 Third Quarter Results work Genentech ... did not meet Genentech s goals. ref name genentech announces Genentech s primary goal was for the drug ... more details
therapies for unmet medical needs as his reason for leaving academia. ref name NYT ref name Genentech ... Executive Vice President Research and Chief Scientific Officer , Genentech . Accessed September 13 ... Genentech Scientist to Lead Rockefeller University , The New York Times , September 8, 2010. Accessed ... 9, 2010. ref He would be the first high ranking science employee to leave Genentech following its acquisition ... culture. Tessier Lavigne stated that his choice to leave Genentech was unrelated to the Roche merger and that this is probably the only job that could have lured me away from Genentech. Russell L ... of the tradition of exchange between academia and Genentech. ref name NYT While it was too early to discuss ... more details
suspension format PDF accessdate 20 February 2009 ref In April 2009, Genentech Inc. announced ... title Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market publisher Genentech, Inc. date 8 April 2009 url http www.drugs.com news genentech announces voluntary raptiva u s market ... more details
David Goeddel born 1951 in San Diego is a pioneer of the biotechnology industry who, employed at the time by Genentech , successfully used genetic engineering to coax bacteria into creating synthetic human insulin , human growth hormone , and human TPA for use in therapeutic medicine. By contrast, the pharmaceutical industries had been researching synthetically created versions of those proteins. Recruited by Robert A. Swanson Bob Swanson in 1978, he was the first non university scientist to be hired ref name Forbes1999 cite web url http members.forbes.com asap 1999 0531 090a 2.html title Biotechnology All Stars author Eric W. Pfeiffer publisher Forbes date 1999 05 31 ref at Genentech , and the company s third employee. ref name Forbes1999 Goeddel became legendary in the biotechnology and molecular biology fields by cloning virtually all of Genentech s early products and or processes, including synthetic insulin , growth hormone , and TPA , often beating out bigger and more established laboratories in the process. Besides being perhaps the single most important contributor to Genentech s rise to one of the nation s premier biotech companies, his extraordinary drive and competitive work ethic embodied Genentech s early Clone or Die culture ref name Invisible Frontiers Invisible Frontiers The Race to Synthesize a Human Gene by Stephen S. Hall 1987, Tempus Books of Microsoft Press ref Together with Steve McKnight and Robert Tjian , he founded Tularik in 1991, and was their president and CEO until Tularik was acquired by Amgen for 1.3 billion dollars in 2004 ref cite web url http www.amgen.com media media pr detail.jsp?year 2004&releaseID 509295 title Amgen to Acquire Tularik for 1.3 Billion date 2004 03 29 author Amgen publisher Amgen ref Goeddel earned his bachelor s degree in chemistry from the University of California, San Diego , and his PhD from the University of Colorado, Boulder . He is a member of the United States National Academy of Sciences National Academy ... more details
refimprove date January 2009 Napoleone Ferrara , M.D. , Ph.D. is an Italian American molecular biologist and is currently a Genentech Fellow in tumor biology and angiogenesis. He is credited with identifying the human Vascular endothelial growth factor VEGF gene and describing its angiogenesis proangiogenic properties, which formed the basis for the development of Genentech s bevacizumab and Lucentis monoclonal antibody treatments. For his VEGF discovery, he won a Lasker Award in 2010. ref cite web url http www.laskerfoundation.org awards 2010 c description.htm title 2010 Winners Lasker DeBakey Clinical Medical Research Award author Strauss, Evelyn publisher The Lasker Foundation accessdate 2010 11 11 ref Education Dr. Ferrara received his medical degree from the Faculty of Medicine and Surgery at the University of Catania , Italy , in 1981 , and joined Genentech in 1988 . ref http www.sciencedirect.com science? ob ArticleURL& udi B6T64 4FYG6N7 5& user 4429& rdoc 1& fmt & orig search& sort d&view c& acct C000059602& version 1& urlVersion 0& userid 4429&md5 0c53e7083cf75f478bba859312458ba4 Napoleone Ferrara discusses Avastin and the future of anti angiogenesis therapy , ScienceDirect. ref References reflist Persondata Metadata see Wikipedia Persondata . NAME Ferrara, Napoleone ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Ferrara, Napoleone Category Year of birth missing living people Category Living people Category Italian scientists Category Molecular biologists italy biologist stub de Napoleone Ferrara ... more details
Other people2 Robert Gentleman disambiguation Robert Gentleman Infobox scientist name Robert Gentleman image Freely licenced images only. Please do not put a fair use image here, it will be deleted see WP NONFREE image size caption Do you have a picture of Robert Gentleman? Please, post here. birth name birth date birth place nationality other names known for R programming language occupation prizes Benjamin Franklin Award Bioinformatics Robert C. Gentleman born 1959 is a Canadian statistician and bioinformatician ref cite doi 10.2202 1544 6115.1034 ref currently working for Genentech . ref cite pmid 21205783 ref ref name genentech http www.gene.com gene research sci profiles bioinfo gentleman profile.html Robert C. Gentleman Senior Director Bioinformatics & Computational Biology ref He is recognized, along with Ross Ihaka , as one of the originators of the R programming language ref cite jstor 1390807 ref ref cite web url http www.nytimes.com 2009 01 07 technology business computing 07program.html title R, the Software, Finds Fans in Data Analysts NYTimes.com author Ashlee Vance date 6 January 2009 work publisher New York Times accessdate 17 April 2011 ref and associated software packages like Bioconductor . ref cite doi 10.1186 gb 2004 5 10 r80 ref He got his Ph.D. degree in Statistics from University of Washington in 1988. ref name genentech Awards Gentleman won the Benjamin Franklin Award Bioinformatics Benjamin Franklin Award in 2008. ref http www.bioinformatics.org franklin http www.bioinformatics.org franklin ref References Reflist Persondata Metadata see Wikipedia Persondata . NAME Gentleman, Robert ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH 1959 PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH DEFAULTSORT Gentleman, Robert Category 1959 births Category Living people Category Bioinformaticians Category Canadian statisticians Category University of Washington alumni ... more details
Drugbox Verifiedfields changed verifiedrevid 464383569 Monoclonal antibody data type mab mab type mab source zu target IFN Clinical data tradename pregnancy AU pregnancy US pregnancy category legal AU legal CA legal UK legal US legal status routes of administration Pharmacokinetic data bioavailability protein bound metabolism elimination half life excretion Identifiers ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID NA CAS number Ref cascite changed ?? CAS number 948570 30 7 ATC prefix none ATC suffix PubChem DrugBank Ref drugbankcite correct drugbank DrugBank UNII Ref fdacite correct FDA UNII LDO2FIQ61I Chemical data chemical formula C 6486 H 9990 N 1722 O 2026 S 44 molecular weight 145.9 kDa Rontalizumab is a humanized monoclonal antibody ref http www.who.int medicines publications druginformation innlists PLFinal101.pdf WHO Drug Information ref being developed by Genentech . ref http www.gene.com gene pipeline status immunology rhumab ifnalpha Genentech Rontalizumab rhuMAb IFN alpha ref as of 2009 11 , it is being investigated in a clinical trial or the treatment of systemic lupus erythematosus . ref ClinicalTrialsGov NCT00962832 A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus ROSE ref References reflist Monoclonals for immune system Category Monoclonal antibodies monoclonal antibody stub antineoplastic drug stub ... more details
unreferenced date May 2010 The Advanced Computation Group ACG is a group within Apple Inc . The ACG researches algorithms and high performance issues relevant to Apple technology. ACG concentrates on Mac OS X for computer science Relationship with other fields scientific applications , vectorization parallel computing vectorization , tutorials, algorithm implementations for specific Apple products and joint research and development with outside partners. One particularly high profile project of the ACG is Apple Genentech BLAST an algorithm for comparing biological sequences, such as the amino acid sequences of different proteins which runs several times faster on Power Mac and Xserve than generic BLAST runs on other platforms. This implementation is open source software developed in cooperation with Genentech . The ACG also developed Apple s Xgrid , which is cluster computing cluster ing and distributed computing software for Macintosh computers, allowing central processing unit processor intensive applications to borrow processing power from other computers on their network. Much of the work of the ACG has been directed toward advanced uses of PowerPC processors which have run Macintosh computers since the 1990s. Now that Apple has completed their Apple Intel transition transition to Intel processors , the ACG s work is increasingly focused on that new platform. External links http www.apple.com acg ACG web site http www.apple.com acg archive.html ACG archive primarily concerned with PPC architecture, but much is also applicable to Intel architecture http developer.apple.com opensource tools blast.html A G BLAST Apple Category Apple Inc. Category Cluster computing ... more details
Unreferenced date December 2006 Tercica, Inc. , is a biopharmaceutical company based in Brisbane, California, USA. It is owned by Ipsen . It is the current developer of Increlex mecasermin rDNA origin injection , also known as recombinant human Insulin like Growth Factor 1 rhIGF 1 . Tercica has applied to the Food and Drug Administration FDA for approval of Increlex as a long term therapy for growth failure in children with severe primary IGF 1 deficiency Primary IGFD , which is characterized by growth faiulre, and as a treatment for children with growth hormone GH gene deletion who have developed neutralizing antibodies to growth hormone. Tercica licensed rights to develop, manufacture, and market Increlex from Genentech , Inc. Increlex is currently in Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD. See also Portal Companies Human growth hormone Human growth hormone HGH IGF 1 Category Companies formerly listed on NASDAQ Category Biotechnology companies biotech stub US corp stub med company stub ... more details
adults. Controversy The MAGIC Foundation received significant funding from Genentech and Eli Lilly ... of children in ... Since then, the Magic Foundation had continued to accept money from Genentech ... 22&f false isbn 0312428251 ref The US Food and Drug Administration investigated Genentech in 1992 ... Genentech, Nonprofit Link Studied Agencies Probe Whether Foundation Helped Sales newspaper Washington ... more details
For other people named Robert Swanson Bob Swanson disambiguation Infobox Person name Robert A. Swanson image Replace this image male.svg image size 150px caption Robert A. Swanson birth name Robert birth date 1947 birth place U.S.A death date 1999 death place death cause brain cancer resting place resting place coordinates residence nationality United States other names known for Genentech , biotechnology education MIT employer occupation biotechnologist home town title salary networth height weight term predecessor successor party boards religion spouse partner children parents relatives signature website footnotes Robert A. Swanson 1947 1999 was a venture capitalist who cofounded the biotechnology giant Genentech in 1976 with Herbert Boyer . Genentech is a pioneer in the field, and it remains one of the leading biotech companies in the world. He held an B.S. degree in Chemistry from MIT as well as a MIT Sloan School of Management Master s degree in Management M.B.A. from the MIT Sloan School of Management . Both degrees were conferred in 1970. He is regarded as an instrumental figure in launching the biotechnology revolution. The authors of the book, 1,000 Years, 1,000 People Ranking the Men and Women Who Shaped the Millennium ranked Mr. Swanson number 612. Mr. Swanson was inducted into the Junior Achievement U. S. Business Hall of Fame in 2006. ref http web.mit.edu newsoffice 1999 swanson 1208.html Robert Swanson, 52, alumnus who launched biotechnology industry, MIT News Office ref On 6 December , 1999, he succumbed to brain cancer , at the age of 52. ref http www.nature.com nature journal v403 n6767 full 403264a0.html Access Nature Bot generated title ref External links http www.accessexcellence.org RC AB BC Robert Swanson.html AccessExcellence.org References Reflist Persondata Metadata see Wikipedia Persondata . NAME Swanson, Robert A. ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH 1947 PLACE OF BIRTH U.S.A DATE OF DEATH 1999 PLACE OF DEATH DEFAULTSORT Swans ... more details
Dr. Arthur Riggs , Ph.D, is a geneticist who worked with Genentech to gene expression express the first artificial gene in bacteria . His work was critical to the modern biotechnology industry because it enabled the large scale manufacturing of protein drugs , including insulin . In 2006, Riggs was elected to the United States National Academy of Sciences National Academy of Sciences . He is the director emeritus of the Beckman Research Institute of City of Hope National Medical Center , where he was also the founding dean of City of Hope s graduate school. Riggs also serves on the board of trustees at the Keck Graduate Institute of Applied Life Sciences . Background Riggs earned his undergraduate degree in chemistry at University of California, Riverside in 1961, and was honored as a distinguished alumnus in 1988 http www.alumni.ucr.edu 50th 50 award recipients.html . He conducted his doctoral thesis work at the California Institute of Technology with Herschel K. Mitchell http www.pnas.org cgi reprint 55 3 599 . As graduate students at Caltech, he and Joel A. Huberman collaborated on work that later led to a classic paper on mammal ian DNA replication , which was published in 1966 http www.ncbi.nlm.nih.gov entrez query.fcgi?cmd Retrieve&db PubMed&list uids 5689363&dopt Citation . His postdoctoral work at the Salk Institute resulted in another well known series of papers on the lac repressor and bacteria l gene regulation . Genentech Along with fellow City of Hope researcher Keiichi Itakura , Riggs collaborated with Genentech scientist Herbert Boyer , and used recombinant DNA technology to become the first to produce a human protein in Escherichia coli E. coli . Following the advice of Riggs and Itakura, the group successfully produced the hormone Somatostatin in 1977 as a proof of concept before they attempted to work with the more complicated insulin molecule. http www.nap.edu books 0309051894 html 167.html The group succeeded in producing insulin in 1978, and in 1979 ... more details
ref Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere ... Lucentis Fact Sheet . Genentech. ref under the brand name Lucentis. Mechanism of action Ranibizumab ... name AustriaCodex Marketing On November 3, 2010, The New York Times reported that Genentech began ... title Genentech Offers Secret Rebates for Eye Drug work The New York Times author Andrew Pollack ... References Reflist External links Official website http www.lucentis.com Genentech Ocular vascular ... more details
2010 small ref name AR2010 subsid Genentech , Ventana Medical Systems Ventana homepage http www.roche.com ... in India. and Rio de Janeiro , Brazil. The company also owns the American biotechnology company Genentech ... acquired Syntex . On 12 March 2009 Roche agreed to fully acquire Genentech , in which it had held a majority stake since 1990, ref cite news url http www.nytimes.com 1990 02 05 business genentech roche deal may spur similar ties.html title Genentech Roche Deal May Spur Similar Ties last Pollack first .... As a result of the Genentech acquisition, Roche closed its Palo Alto based research facilities and moved them to Nutley while the US Headquarters in Nutley was moved to Genentech s facility ... sectors health article5897691.ece title Roche swallows Genentech in third large drugs deal last Bawden first Tom work The Times date 13 March 2009 accessdate 2009 04 11 location London ref Genentech ... article mergersNews idUSLQ73529820090326 title Roche completes Genentech buy last Jucca first Lisa ... more details
Encyclopedia
top
